Glenmark gets nod to launch favipiravir for treatment of COVID-19 patients

20 Jun 2020 Evaluate

Glenmark Pharmaceuticals has received the manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients in India.

This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Glenmark Pharmaceuticals (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma Share Price

1986.75 -5.95 (-0.30%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×